Obesity
Conditions
Keywords
GLP2, Obesity, Premenopausal, Bone, Formation, Resorption
Brief summary
This study has been designed to study differences bone turnover in relation to glucagon-like peptide-2 (GLP-2) following feeding in lean and obese premenopausal women. Given the preliminary evidence that GLP-2 may act directly on osteoclasts, the investigators plan to determine whether GLP2 receptors are expressed in osteoclasts and the effect of GLP-2 on bone resorption. Hypotheses: 1. Acute responses of GLP-2 and bone resorption markers following feeding are affected by body fat mass. 2. Serum levels of GLP-2 are lower in obese pre-menopausal women and are associated with a reduction in trabecular and/or cortical bone mass 3. GLP-2 has direct actions on osteoclast resorption via a functional receptor
Detailed description
Study objectives: 1. To determine if differences in baseline serum levels of GLP-2 are related to differences in bone microarchitecture, structure and strength at the distal tibia and distal radius between obese and lean premenopausal females. 2. To determine whether obesity in premenopausal females influences levels of circulating GLP-2 following a standardised glucose meal with a resultant change in markers of bone formation and resorption 3. To test whether GLP-2 directly affects osteoclast function via an identifiable receptor
Interventions
OTHERStudy visit procedures
Anthropometric measurements to include: * Weight, height, and BMI. * Waist and hip circumference * Triceps skinfold thickness * Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.
Sponsors
University of Sheffield
Sheffield Teaching Hospitals NHS Foundation Trust
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 25-40 * Caucasian * Premenopausal * Able and willing to consent * BMI either 18.5-24.9 kg/m2 or ≥30 kg/m2 * Completion 'The Effects of Obesity on Bone Structure and Strength' study REC ref 10/H1308/61 * Consented to be approached for future research studies
Exclusion criteria
* Fracture less than twelve months prior to recruitment * History of any long term immobilization (duration greater than three months) * Current pregnancy or trying to conceive Pregnancy or breast feeding less than one year prior to recruitment * Diabetes mellitus * History of or current conditions known to affect bone metabolism, which may include: * Diagnosed skeletal disease or osteoarthritis * Chronic renal disease * Acute or chronic hepatic disease * Hyperparathyroidism or Hyperthyroidism * Malabsorption syndromes * Diagnosed endocrine disorders * Diagnosed diabetes mellitus * Clinically significant hypocalcemia or hypercalcemia * Diagnosed restrictive eating disorder * Current or clinically significant previous use of medications or treatment known to affect bone metabolism, for example: * Depot medroxyprogesterone or the combined oral contraceptive pill * Glucocorticoid therapy * Anti-convulsant therapy * Bone treatments (e.g. Bisphosphonates) * Alcohol intake of greater than 21 units per week * Athlete, defined as an individual participating in competitive sport at amateur or professional level * Monogenic and obesity syndromes * History of cancer within the past 5 years excluding skin cancer non melanomas
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GLP-2 levels | Change at 20, 60 and 120 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Osteocalcin levels | Change at 20, 60 and 120 minutes |
| β Carboxy-terminal collagen crosslinks (β CTx)levels | Change at 20, 60 and 120 minutes |
| Procollagen 1 N-terminal propeptide (P1NP) levels | Change at 20, 60 and 120 minutes |
| High-resolution peripheral quantitative computed tomography (HRpQCT) | At baseline |
| Dual-emission X-ray absorptiometry (DXA) | At baseline |
Countries
United Kingdom
Outcome results
None listed